Century Therapeutics (IPSC) Fundamental Analysis: Revenue, Earnings & Valuation

4.57 / 10

Netural

Fundamental analysis rates IPSC neutral (overall 5.5/10). Positive drivers include PB‑ROE, Cash‑MV and Revenue‑MV, while Asset‑MV and Income‑Tax/Profit lag. Composite score 4.57 reflects balanced valuation, with inventory turnover and gross margin supporting modest strength.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight24.16%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value1556.76

Score1/3

Weight-5.47%

1M Return-3.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.31%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.49%

1M Return1.69%

PB-ROE

Value-0.68

Score2/3

Weight14.49%

1M Return6.97%

Income tax / Total profit (%)

Value0.70

Score1/3

Weight-0.88%

1M Return-0.50%

Fixed assets turnover ratio

Value1.39

Score2/3

Weight-1.02%

1M Return-0.51%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.86%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight27.46%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight13.60%

1M Return5.94%

Is IPSC undervalued or overvalued?

IPSC scores 4.57/10 on fundamentals and holds a Fair valuation at present. Backed by its -5.98% ROE, -8.78% net margin, -39.96 P/E ratio, 2.41 P/B ratio, and 91.30% earnings growth, these metrics solidify its Netural investment rating.